GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2024 Earnings Call Transcript April 29, 2024 GeneDx Holdings Corp. beats earnings expectations. Reported EPS is $-0.33, expectations were $-0.68. GeneDx Holdings Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank […]
Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross.
GeneDx Holdings shares gained 40% in recent Monday trading after the company reported preliminary Q4 and 2023 revenue expectations that topped consensus.
Preliminary Q4 total revenue is expected.